英夫利昔单抗治疗溃疡性结肠炎无效的影响因素分析

Analysis of Influencing Factors for the Ineffectiveness of Infliximab in the Treatment of Ulcerative Colitis

目的 分析英夫利昔单抗治疗溃疡性结肠炎无效的相关影响因素。方法 选取2020年1月至2020年12月襄城县人民医院收治的80例溃疡性结肠炎患者作为研究对象,收集患者性别、年龄以及治疗前Sutherland疾病活动指数(DAI)评分、红细胞沉降率(ESR)和血红蛋白(Hb)、C反应蛋白(CRP)、转化生长因子-β(TGF-β)、白细胞介素-10 (IL-10)水平等资料,根据英夫利昔单抗治疗6周后的临床疗效将患者分为有效组和无效组,多因素Logistic回归分析英夫利昔单抗治疗溃疡性结肠炎无效的相关影响因素。结果 80例溃疡性结肠炎患者经英夫利昔单抗治疗后完全缓解32例、有效33例(有效率为81.25%),设为有效组;无效15例(无效率为18.75%),设为无效组。多因素Logistic回归分析结果显示,治疗前血清TGF-β、IL-10水平低是英夫利昔单抗治疗溃疡性结肠炎无效的独立危险因素(95%CI为1.092~1.363、1.239~2.198,P<0.001、P=0.001)。结论 治疗前血清TGF-β、IL-10水平可影响英夫利昔单抗治疗溃疡性结肠炎的临床效果。

Objective To analyze the related influencing factors resulting in the ineffectiveness of Infliximab in the treatment of ulcerative colitis.Methods 80 patients with ulcerative colitis,admitted to Xiangcheng People’s Hospital from January 2020 to December 2020,were enrolled as research subjects,and data were collected including sex,age,and Sutherland disease activity index(DAI) score and levels of erythrocyte sedimentation rate(ESR),hemoglobin(HB),C-reactive protein(CRP),transforming growth factor-β(TGF-β) and interleukin-10(IL-10) before treatment.Patients were divided into effective group and ineffective group based on the clinical efficacy after six weeks of treatment with lnfliximab.Multivariate Logistic regression analysis was conducted to analyze the related factors influencing the ineffectiveness of Infliximab in treating ulcerative colitis.Results Of the 80 patients with ulcerative colitis treated with Infliximab,32 cases with their symptoms completely relieved and 33 cases showing treatment effectiveness,with the effective rate being81.25%,were set as effective group,and the left 15 cases showed treatment ineffectiveness,with the ineffective rate being18.75%,were set as ineffective group.The result of multivariate Logistic regression analysis showed that low levels of serum TGF-β and IL-10 before treatment were independent risk factors for the ineffectiveness of Infliximab in the treatment of ulcerative colitis(95% CI:1.092-1.363,1.239-2.198,P <0.001,P=0.001).Conclusion The levels of serum TGF-β and IL-10 before treatment can affect the clinical efficacy of Infliximab in the treatment of ulcerative colitis.